Zoetis Inc. (NYSE:ZTS) Shares Acquired by Procyon Advisors LLC

Procyon Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 3.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,512 shares of the company’s stock after acquiring an additional 145 shares during the period. Procyon Advisors LLC’s holdings in Zoetis were worth $891,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ZTS. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the period. VitalStone Financial LLC purchased a new stake in Zoetis during the 1st quarter worth about $37,000. Evermay Wealth Management LLC increased its holdings in Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Worth Asset Management LLC purchased a new stake in Zoetis during the 1st quarter worth about $26,000. Finally, VisionPoint Advisory Group LLC purchased a new stake in Zoetis during the 2nd quarter worth about $29,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. BNP Paribas initiated coverage on Zoetis in a report on Thursday, December 7th. They set an “outperform” rating and a $237.00 price target on the stock. Piper Sandler upped their price target on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus upped their price objective on Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a research report on Friday, January 12th. Finally, The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $224.33.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the completion of the sale, the executive vice president now directly owns 17,569 shares of the company’s stock, valued at approximately $3,363,233.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is owned by company insiders.

Zoetis Stock Performance

Shares of NYSE ZTS traded up $0.57 during trading hours on Thursday, reaching $169.08. The stock had a trading volume of 297,821 shares, compared to its average volume of 2,687,886. The firm has a market cap of $77.42 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.53 and a beta of 0.87. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92. The firm has a 50-day moving average of $186.36 and a 200-day moving average of $182.34.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the company earned $1.15 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. Equities research analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.02%. Zoetis’s payout ratio is 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.